Abstract
Pediatric pharmacological cognitive enhancement (PPCE) refers to children’ and adolescents’ nonmedical use of prescription and recreational drugs for enhanced performance at school. Adolescents’ own intentional decision for substance use to compete with fellow students must be distinguished from parental decisions to enhance their children’s performance as an investment in their children’s or in their own future, respectively. While several recent studies have examined the prevalence and the correlates of pharmacological cognitive enhancement among healthy students and employees, only little is known about PPCE among school students. Given that decision-making in adolescence is strongly modulated by emotional and social factors, peer influence, and availability, the theory of self-medication might best explain intentional PPCE in late adolescence. In addition, regular recreational drug use is likely to lower the barriers for PPCE in populations interested in enhancing their performance at school. To ensure equal developmental opportunities for today’s school students, an individual-centered approach should focus on strengthening adolescents’ resources and self-efficacy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albert D, Chein J, Steinberg L (2013) Peer influences on adolescent decision making. Curr Dir Psychol Sci 22(2):114–120. https://doi.org/10.1177/0963721412471347
Arria AM, DuPont RL (2010) Nonmedical prescription stimulant use among college students: why we need to do something and what we need to do. J Addict Dis 29(4):417–426. https://doi.org/10.1080/10550887.2010.509273
Arria AM, Caldeira KM, Vincent KB, O’Grady KE, Cimini MD, Geisner IM et al (2016) Do college students improve their grades by using prescription stimulants nonmedically? Addict Behav 65:245. https://doi.org/10.1016/j.addbeh.2016.07.016
Austic EA (2015) Peak ages of risk for starting nonmedical use of prescription stimulants. Drug Alcohol Depend 152:224–229. https://doi.org/10.1016/j.drugalcdep.2015.03.034
Bagot KS, Kaminer Y (2014) Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction 109(4):547–557. http://www.ncbi.nlm.nih.gov/pubmed/24749160.
Bandura A (1977) Self-efficacy: toward an unifying theory of behavioral change. Psychol Rev 84(2):191–215
Bardo MT, Neisewander JL, Kelly TH (2013) Individual differences and social influences on the neurobehavioral pharmacology of abused drugs. Pharmacol Rev 65(1):255–290. https://doi.org/10.1124/pr.111.005124
Baumeister RF, Campbell JD, Krueger JI, Vohs KD (2003) Does high self-esteem cause better performance, interpersonal success, happiness, or healthier lifestyles? Psychol Sci Public Interest 4(1):1–44. https://doi.org/10.1111/1529-1006.01431
Bell S, Partridge B, Lucke J, Hall W (2012) Australian University students’ attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics 6(1):197–205. https://doi.org/10.1007/s12152-012-9153-9
Blakemore SJ, Robbins TW (2012) Decision-making in the adolescent brain. Nat Neurosci 15(9):1184–1191. https://doi.org/10.1038/nn.3177
Boot BP, Partridge B, Hall W (2012) Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase 18(3):181–184. https://doi.org/10.1080/13554794.2011.588174
Brinkman WB, Epstein JN (2011) Promoting productive interactions between parents and physicians in the treatment of children with attention-deficit/hyperactivity disorder. Expert Rev Neurother 11(4):579–588. https://doi.org/10.1586/ern.10.151
Butcher J (2003) Cognitive enhancement raises ethical concerns. Lancet 362(9378):132–133. www.thelancet.com
Compton WM, Volkow ND (2006) Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 83(Suppl 1):S4–S7. https://doi.org/10.1016/j.drugalcdep.2005.10.020
Dietz P, Striegel H, Franke AG, Lieb K, Simon P, Ulrich R (2013) Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy 33(1):44–50. https://doi.org/10.1002/phar.1166
Drabiak-Syed K (2011) Physicians prescribing “medicine” for enhancement: why we should not and cannot overlook safety concerns. Am J Bioeth 11(1):17–19. https://doi.org/10.1080/15265161.2010.534535
Erikson EH (1968) Identity, youth and crisis. Norton, New York
Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P et al (2004) Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 5(5):421–425. https://doi.org/10.1038/nrn1390
Forlini C, Gauthier S, Racine E (2013) Should physicians prescribe cognitive enhancers to healthy individuals? Can Med Assoc J 185(12):1047–1050. https://doi.org/10.1503/cmaj.121508
Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt E, Lieb K (2011) Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 44(2):60–66. https://doi.org/10.1055/s-0030-1268417
Graf WD, Nagel SK, Epstein LG, Miller G, Nass R, Larriviere D (2013) Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications. Neurology 80(13):1251–1260. https://doi.org/10.1212/WNL.0b013e318289703b
Hiatt C, Laursen B, Stattin H, Kerr M (2017) Best friend influence over adolescent problem behaviors: socialized by the satisfied. J Clin Child Adolesc Psychol 46(5):695–708. https://doi.org/10.1080/15374416.2015.1050723
Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE (2016) Monitoring the future national survey results on drug use, 1975-2015: overview, key findings on adolescent drug use. Institute for Social Research, University of Michigan, Ann Arbor. http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2011.pdf
Kaye S, Darke S (2012) The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction 107(3):467–477. https://doi.org/10.1111/j.1360-0443.2011.03720.x
Khantzian EJ (1997) The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry 4(5):231–244. http://informahealthcare.com/doi/abs/10.3109/10673229709030550
Liakoni E, Schaub MP, Maier LJ, Glauser GV, Liechti ME (2015) The use of prescription drugs, recreational drugs, and “soft enhancers” for cognitive enhancement among Swiss Secondary School Students. PLoS One 10(10):e0141289. https://doi.org/10.1371/journal.pone.0141289
Maier LJ, Schaub MP (2015) The use of prescription drugs and drugs of abuse for neuroenhancement in Europe. Eur Psychol 20(3):155–166. https://doi.org/10.1027/1016-9040/a000228
Maier LJ, Liechti ME, Herzig F, Schaub MP (2013) To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss University Students. PLoS One 8(11):e77967. https://doi.org/10.1371/journal.pone.0077967
Maier LJ, Haug S, Schaub MP (2015a) The importance of stress, self-efficacy, and self-medication for pharmacological neuroenhancement among employees and students. Drug Alcohol Depend 156:221–227. https://doi.org/10.1016/j.drugalcdep.2015.09.012
Maier LJ, Liakoni E, Schildmann J, Schaub MP, Liechti ME (2015b) Swiss University students’ attitudes toward pharmacological cognitive enhancement. PLoS One 10(12):e0144402. https://doi.org/10.1371/journal.pone.0144402
Maier LJ, Wunderli MD, Vonmoos M, Römmelt AT, Baumgartner MR, Seifritz E et al (2015c) Pharmacological cognitive enhancement in healthy individuals: a compensation for cognitive deficits or a question of personality? PLoS One 10(6):e0129805. https://doi.org/10.1371/journal.pone.0129805
Maier LJ, Haug S, Schaub MP (2016) Prevalence of and motives for pharmacological neuroenhancement in Switzerland-results from a national internet panel. Addiction 111(2):280–295. https://doi.org/10.1111/add.13059
Middendorff E, Poskowsky J, Isserstedt W (2012) Formen der Stresskompensation und Leistungssteigerung bei Studierenden. HIS, Hannover
Nagel S, Stephan A (2009) Was bedeutet Neuro-Enhancement? Potentiale, Konsequenzen, ethische Dimensionen. In: Schöne-Seifert B, Talbot D, Johann S (eds) Neuro Enhancement, Ethik vor neuen Herausforderungen. Mentis Verlag, Padborn, pp 19–47
NICE (2018) Attention deficit hyperactivity disorder: diagnosis and management | guidance and guidelines | NICE. NICE. https://www.nice.org.uk/guidance/NG87
Ott R, Lenk C, Miller N, Neuhaus Bühler R, Biller-Andorno N (2012) Neuroenhancement—perspectives of Swiss psychiatrists and general practitioners. Swiss Medical Weekly, 142(November):w13707. https://doi.org/10.4414/smw.2012.13707
Partridge B, Bell S, Lucke J, Hall W (2013) Australian university students’ attitudes towards the use of prescription stimulants as cognitive enhancers: perceived patterns of use, efficacy and safety. Drug Alcohol Rev 32(3):295–302. https://doi.org/10.1111/dar.12005
Ponnet K, Wouters E, Van Hal G, Heirman W, Walrave M (2014) Determinants of physicians’ prescribing behaviour of methylphenidate for cognitive enhancement. Psychol Health Med 19(3):286–295. https://doi.org/10.1080/13548506.2013.802361
Racine E, Forlini C (2010) Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Neuroethics 3(1):1–4. https://doi.org/10.1007/s12152-008-9023-7
Rasmussen N (2008) On speed: the many lives of amphetamine. http://books.google.ch/books/about/On_Speed.html?id=1mf5eEG0nRUC&pgis=1
Ray KS (2016) Not just “study drugs” for the rich: stimulants as moral tools for creating opportunities for socially disadvantaged students. Am J Bioeth 16(6):29–38. https://doi.org/10.1080/15265161.2016.1170231
Repantis D (2013) Psychopharmacological neuroenhancement: evidence on safety and efficacy. In: Hildt E, Franke AG (eds) Cognitive enhancement: an interdisciplinary perspective, vol 1. Springer, Dordrecht, pp 29–38. https://doi.org/10.1007/978-94-007-6253-4
Sabini J, Monterosso J (2005) Judgments of the fairness of using performance enhancing drugs. Ethics Behav 15(1):81–94. https://doi.org/10.1207/s15327019eb1501_6
Sattler S, Singh I (2016) Cognitive enhancement in healthy children will not close the achievement gap in education. Am J Bioeth 16(6):39–41. https://doi.org/10.1080/15265161.2016.1170240
Schelle KJ, Faulmüller N, Caviola L, Hewstone M (2014) Attitudes toward pharmacological cognitive enhancement—a review. Front Syst Neurosci 8:53. https://doi.org/10.3389/fnsys.2014.00053
Sherman LE, Payton AA, Hernandez LM, Greenfield PM, Dapretto M (2016) The power of the like in adolescence. Psychol Sci 27(7):1027–1035. https://doi.org/10.1177/0956797616645673
Singh I, Kelleher KJ (2010) Neuroenhancement in young people: proposal for research, policy, and clinical management. AJOB Neurosci 1(1):3–16. https://doi.org/10.1080/21507740903508591
Singh I, Filipe AM, Bard I, Bergey M, Baker L (2013) Globalization and cognitive enhancement: emerging social and ethical challenges for ADHD clinicians. Curr Psychiatry Rep 15(9):385. https://doi.org/10.1007/s11920-013-0385-0
Teter CJ, McCabe SE, Cranford J a, Boyd CJ, Guthrie SK (2005) Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 53(6):253–262. https://doi.org/10.3200/JACH.53.6.253-262
Volkow ND, Swanson JM (2008) The action of enhancers can lead to addiction. Nature 451(7178):520. https://doi.org/10.1038/451520a
Wilens TE, Adler L, Adams J, Sgambati S, Rotrosen J, Sawtelle R et al (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47(1):21–31. https://doi.org/10.1097/chi.0b013e31815a56f1
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM et al (2011) ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5):1007–1022. https://doi.org/10.1542/peds.2011-2654
Wood S, Sage JR, Shuman T, Anagnostaras SG (2014) Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol Rev 66(1):193–221. https://doi.org/10.1124/pr.112.007054
Wulf MA, Joksimovic L, Tress W (2011) Das Ringen um Sinn und Anerkennung – Eine psychodynamische Sicht auf das Phänomen des Neuroenhancement (NE). Ethik Der Medizin 24(1):29–42. https://doi.org/10.1007/s00481-011-0137-9
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Maier, L.J. (2019). Pediatric Pharmacological Cognitive Enhancement in a Self-Medicating Society. In: Nagel, S. (eds) Shaping Children. Advances in Neuroethics. Springer, Cham. https://doi.org/10.1007/978-3-030-10677-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-10677-5_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10676-8
Online ISBN: 978-3-030-10677-5
eBook Packages: MedicineMedicine (R0)